Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ: DNTH )

22.53 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 22.53
Bid (Size) 15.01 (2)
Ask (Size) 36.06 (2)
Prev. Close 22.53
Today's Range 22.53 - 22.53
52wk Range 6.580 - 33.77
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
Via Benzinga
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+96.77%
+96.77%
1 Month
-24.19%
-24.19%
3 Month
+18.58%
+18.58%
6 Month
+87.75%
+87.75%
1 Year
+104.82%
+104.82%

More News

Read More
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Decoding 4 Analyst Evaluations For Dianthus Therapeutics
Via Benzinga
Why Dianthus Therapeutics (DNTH) Stock Is Exploding Higher
Via Benzinga
DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023
Via InvestorPlace
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
Via Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.